[
1. Ackaert, C., Smiejkowska, N., Xavier, C., Sterckx, Y. G. J., Denies, S., Stijlemans, B., et al., 2021: Immunogenicity risk profile of nanobodies. Front. Immunol., 12, 632‒687. DOI: 10.3389/fimmu.2021.632687.
]Search in Google Scholar
[
2. Ballabh, P., Braun, A., Nedergaard, M., 2004: The blood-brain barrier: An overview: Structure, regulation, and clinical implications. Neurobiol. Dis., 16, 1, 1‒13. DOI: 10.1016/j. nbd.2003.12.016.
]Search in Google Scholar
[
3. Bannas, P., Hambach, J., Koch-Nolte, F., 2017: Nano-bodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front. Immunol., 8, 1603. DOI: 10.3389/fimmu.2017.01603.
]Search in Google Scholar
[
4. Bhunia, S., Kolishetti, N., Vashist, A., Yndart Arias, A., Brooks, D., Nair, M., 2023: Drug delivery to the brain: Recent advances and unmet challenges. Pharmaceutics., 15, 12, 2658. DOI: 10.3390/pharmaceutics15122658.
]Search in Google Scholar
[
5. Birdhariya, B., Kesharwani, P., Jain, N. K., 2015: Effect of surface capping on targeting potential of folate decorated poly (propylene imine) dendrimers. Drug Dev. Ind. Pharm., 41, 8, 1393‒1399. DOI: 10.3109/03639045.2014.954584.
]Search in Google Scholar
[
6. Bowers, K. M., Mudrakola, V., 2020: Neuroinfections: Presentation, diagnosis, and treatment of meningitis and encephalitis. EMJ Neurology, 8, 1, 9‒102. DOI: 10.33590/emjneurol/20-00063.
]Search in Google Scholar
[
7. De Vos, J., Devoogdt, N., Lahoutte, T., Muyldermans, S., 2013: Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target. Expert Opin. Biol. Ther., 13, 8, 1149–1160. DOI: 10.1517/14712598.2013.800478.
]Search in Google Scholar
[
8. Demeule, M., Currie, J. C., Bertrand, Y., Ché, C., Nguyen, T., Régina, A., et al., 2008: Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem., 106, 4, 534‒44. DOI: 10.1111/j.1471-4159.2008.05492.x.
]Search in Google Scholar
[
9. Dumoulin, M., Conrath, K., Van Meirhaeghe, A., Meersman, F., Heremans, K., Frenken, L. G., et al., 2002: Single-domain antibody fragments with high conformational stability. Protein Sci., 11, 3, 500‒515. DOI: 10.1110/ps.34602.
]Search in Google Scholar
[
10. Ellul, M., Solomon, T., 2018: Acute encephalitis ‒ diagnosis and management. Clin. Med., 18, 2, 155‒159. DOI: 10.7861/clinmedicine.18-2-155.
]Search in Google Scholar
[
11. Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Songa, E. B., et al., 1993: Naturally occurring antibodies devoid of light chains. Nature, 363, 6428, 446‒448. DOI: 10.1038/363446a0.
]Search in Google Scholar
[
12. Henry, K. A., MacKenzie, C. R., 2018: Antigen recognition by single-domain antibodies: structural latitudes and constraints. MAbs., 10, 6, 815‒826. DOI: 10.1080/19420862.2018.1489633.
]Search in Google Scholar
[
13. Hillman, Y., Lustiger, D., Wine, Y., 2019: Antibody-based nanotechnology. Nanotechnology, 30, 28, 282001. DOI: 10.1088/1361-6528/ab12f4.
]Search in Google Scholar
[
14. Holliger, P., Hudson, P. J., 2005: Engineered antibody fragments and the rise of single domains. Nat. Biotechnol., 23, 9, 1126‒1136. DOI: 10.1038/nbt1142.
]Search in Google Scholar
[
15. Hořejší, V., Bartůňková, J., Brdlička, T., Špíšek, R., 2017: Basics of Immunology (In Czech). 6th edn., Triton, Prague, 316 pp.
]Search in Google Scholar
[
16. Hruškovicová, J., Bhide, K., Petroušková, P., Tkáčová, Z., Mochnáčová, E., Čurlík, J., et al., 2022: Engineering the single domain antibodies targeting receptor binding motifs within the domain III of West Nile virus envelope glycoprotein. Front. Microbiol., 13, 801466. DOI: 10.3389/fmicb.2022.801466.
]Search in Google Scholar
[
17. Jin, S., Ye, K., 2007: Nanoparticle-mediated drug delivery and gene therapy. Biotechnol. Prog., 23, 1, 32‒41. DOI: 10.1021/bp060348j.
]Search in Google Scholar
[
18. Jovčevska, I., Muyldermans, S., 2020: The therapeutic potential of nanobodies. BioDrugs, 34, 1, 11‒26. DOI: 10.1007/s40259-019-00392-z.
]Search in Google Scholar
[
19. Kadry, H., Noorani, B., Cucullo, L., 2020: A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS, 17, 1, 69. DOI: 10.1186/s12987-020-00230-3.
]Search in Google Scholar
[
20. Leber, A. L., Everhart, K., Balada-Llasat, J. M., Cullison, J., Daly, J., Holt, S., et al., 2016: Multicenter evaluation of BioFire FilmArray Meningitis/Encephalitis Panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens. J. Clin. Microbiol., 54, 9, 2251‒2261. DOI: 10.1128/JCM.00730-16.
]Search in Google Scholar
[
21. Li, Z., Liu, T., Yang, N., Han, D., Mi, X., Li, Y., et al., 2020: Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain. Front. Med., 14, 5, 533‒541. DOI: 10.1007/s11684-020-0786-5.
]Search in Google Scholar
[
22. Lyons, T. W., McAdam, A. J., Cohn, K. A., Monuteaux, M. C., Nigrovic, L. E., 2012: Impact of in-hospital enteroviral polymerase chain reaction testing on the clinical management of children with meningitis. J. Hosp. Med., 7, 7, 517‒520. DOI: 10.1002/jhm.1947.
]Search in Google Scholar
[
23. Masserini, M., 2013: Nanoparticles for brain drug delivery. ISRN Biochem., 238428. DOI: 10.1155/2013/238428.
]Search in Google Scholar
[
24. Minatel, V. M., Prudencio, C. R., Barraviera, B., Ferreira, R.S., 2024: Nanobodies: A promising approach to treatment of viral diseases. Front. Immunol., 14. DOI:10.3389/fimmu.2023.1303353.
]Search in Google Scholar
[
25. Muyldermans, S., 2013: Nanobodies: Natural single-domain antibodies. Annu. Rev. Biochem., 82, 775‒797. DOI: 10.1146/annurev-biochem-063011-092449.
]Search in Google Scholar
[
26. Pardridge, W. M., 2012: Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab., 32, 11, 1959‒1972. DOI: 10.1038/jcbfm.2012.126.
]Search in Google Scholar
[
27. Pethő, L., Oláh-Szabó, R., Mező, G., 2023: Influence of the drug position on bioactivity in Angiopep-2—Daunomycin conjugates. Int. J. Mol. Sci., 24, 4, 3106. DOI: 10.3390/ijms24043106.
]Search in Google Scholar
[
28. Pothin, E., Lesuisse, D., Lafaye, P., 2020: Brain delivery of single-domain antibodies: A focus on VHH and VNAR. Pharmaceutics, 12, 10, 937. DOI: 10.3390/pharmaceutics12100937.
]Search in Google Scholar
[
29. Qiu, L., Feng, Y., Ma, X., Li, J., 2017: A camel anti-lysozyme CDR3 only domain antibody selected from phage display VHH library acts as potent lysozyme inhibitor. Acta Biochim. Biophys. Sin., 49, 6, 513‒519. DOI: 10.1093/abbs/gmx037.
]Search in Google Scholar
[
30. Roux, K. H., Greenberg, A. S., Greene, L., Strelets, L., Avila, D., McKinney, E. C., et al., 1998: Structural analysis of the nurse shark (new) antigen receptor (NAR): Molecular convergence of NAR and unusual mammalian immunoglobulins. Proc. Natl. Acad. Sci. U.S.A., 95, 20, 11804‒11809. DOI: 10.1073/pnas.95.20.11804.
]Search in Google Scholar
[
31. Ruiz-López, E., Schuhmacher, A. J., 2021: Transportation of single-domain antibodies through the blood-brain barrier. Biomolecules, 11, 8, 1131. DOI: 10.3390/biom11081131.
]Search in Google Scholar
[
32. Salvador, J. P., Vilaplana, L., Marco, M. P., 2019: Nano-body: Outstanding features for diagnostic and therapeutic applications. Anal. Bioanal. Chem., 411, 9, 1703‒1713. DOI: 10.1007/s00216-019-01633-4.
]Search in Google Scholar
[
33. Stanimirovic, D., Kemmerich, K., Haqqani, A. S., Farrington, G. K., 2014: Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies. Adv. Pharmacol., 71, 301‒335. DOI: 10.1016/bs.apha.2014.06.005.
]Search in Google Scholar
[
34. Steeland, S., Vandenbroucke, R. E., Libert, C., 2016: Nanobodies as therapeutics: Big opportunities for small antibodies. Drug Discov. Today, 21, 7, 1076‒1113. DOI: 10.1016/j.drudis.2016.04.003.
]Search in Google Scholar
[
35. Tanski, M. E., Ma, O. J., 2020: Central nervous system and spinal infections. In Tintinalli’s Emergency Medicine: A Comprehensive Study Guide. 9th edn., McGraw-Hill Education: New York, NY. Available online at https://accessmedicine.mhmedical.com/content.aspx?
]Search in Google Scholar
[
36. Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., et al., 2020: Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv., 12, 21. DOI: 10.1101/2020.12.21.20248640.
]Search in Google Scholar
[
37. Tyagi, K., Rai, P., Gautam, A., Kaur, H., Kapoor, S., Suttee, A., et al., 2023: Neurological manifestations of SARSCoV-2: complexity, mechanism and associated disorders. Eur. J. Med. Res., 28, 1, 307. DOI: 10.1186/s40001-023-01293-2.
]Search in Google Scholar
[
38. Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juarez, K., Urrutia, M., et al., 2009: Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity. Med. Microbiol. Immunol., 198, 3, 157‒174. DOI: 10.1007/s00430-009-0116-7.
]Search in Google Scholar
[
39. Wevers, N. R., De Vries, H. E., 2023: Microfluidic models of the neurovascular unit: A translational view. Fluids Barriers CNS, 20, 1, 86. DOI: 10.1186/s12987-023-00490-9.
]Search in Google Scholar
[
40. Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., et al., 2020: A new coronavirus associated with human respiratory disease in China. Nature, 579, 7798, 265‒269. DOI: 10.1038/s41586-020-2008-3.
]Search in Google Scholar
